Drugs / Trivax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01213407 | Apr 2010 → Jun 2015 | glioblastoma | Activartis Biotech | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01213407 ↗ |
| Modality | Cell therapy | “Trivax therefore represents a fully individualised somatic cell therapy medicine.” NCT01213407 ↗ |